September 30, 2019 / 6:51 AM / 3 months ago

BRIEF-Roche To Announce Positive Results From Study Using Blood-Based NGS To Detect Specific Fusions

Sept 30 (Reuters) - Roche Holding AG:

* WILL TODAY ANNOUNCE POSITIVE RESULTS FROM A SINGLE-ARM COHORT OF THE PHASE II/III BLOOD FIRST ASSAY SCREENING TRIAL (BFAST), THE FIRST PROSPECTIVE STUDY TO USE ONLY BLOOD-BASED NEXT GENERATION SEQUENCING (NGS) TO DETECT SPECIFIC FUSIONS Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below